Published in TB and Outbreaks Week, April 25th, 2006
"The introduction of HAART has led to consistent improvements in survival among HIV-infected individuals. However, there is evidence that not all populations have benefited equally from HAART and that mortality rates are higher in HIV-infected injection drug users than in nonusers," scientists in Canada report.
E. Lloyd-Smith and colleagues at the British Columbia Center for Excellence in HIV/AIDS in Vancouver conducted a design-based study of HIV-positive persons in British Columbia's HIV/AIDS treatment program to "model life expectancies for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.